Journal
CANCER CELL
Volume 22, Issue 1, Pages 21-35Publisher
CELL PRESS
DOI: 10.1016/j.ccr.2012.05.037
Keywords
-
Categories
Funding
- National Institutes of Health [RO1CA099948, RO1CA113382, U54CA163155]
- Canadian Institutes of Health Research [CTP-79857]
- Leonard Heyman/American Brain Tumor Association Fellowship
Ask authors/readers for more resources
Inhibition of VEGF signaling leads to a proinvasive phenotype in mouse models of glioblastoma multiforme (GBM) and in a subset of GBM patients treated with bevacizumab. Here, we demonstrate that vascular endothelial growth factor (VEGF) directly and negatively regulates tumor cell invasion through enhanced recruitment of the protein tyrosine phosphatase 1B (PTP1B) to a MET/VEGFR2 heterocomplex, thereby suppressing HGF-dependent MET phosphorylation and tumor cell migration. Consequently, VEGF blockade restores and increases MET activity in GBM cells in a hypoxia-independent manner, while inducing a program reminiscent of epithelial-to-mesenchymal transition highlighted by a T-cadherin to N-cadherin switch and enhanced mesenchymal features. Inhibition of MET in GBM mouse models blocks mesenchymal transition and invasion provoked by VEGF ablation, resulting in substantial survival benefit.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available